Global Cardiac Biomarkers Market By Type (Myoglobin, Troponin, BNP and NT-proBNP, CK-MB, and Other Types) By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Other Indications), By Location of Testing, By Region and Companies – Industry Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Cardiac Biomarkers Market Size was valued at US$ 11.8 Billion in 2022. Between 2023 and 2032, this market is estimated to register the highest CAGR of 12% and is estimated to reach US$ 35.6 Billion by 2032.

Biomarkers are the specific endogenous substances like hormones, proteins, and enzymes that are released into the bloodstream when any cardiovascular condition happens, indicating an abnormality in cardiac functioning.

Many professionals in the healthcare sector are focusing on the detection of these biomarkers, which alert the patient about cardiac abnormality. This includes cardiac abnormalities like heart attack, acute coronary syndrome, myocardial infarction, and many such cardiac-related abnormalities. The researchers have invented various tests to timely and accurately detect the biomarkers in blood that can help to early diagnose cardiac abnormalities.

Many key players in the global cardiac biomarkers market have introduced various testing kits for the detection of cardiac biomarkers. These kits help to easily diagnose cardiac abnormality and give quick results to the user. It also helps the user to diagnose chest pain and other indications prior to adverse cardiac events. Cardiovascular diseases are one of the major causes of death in recent times. Therefore, the importance of cardiac biomarkers has increased significantly in recent times.

Key Takeaways

• Market Growth: The market grew to US$11.8 billion in 2022, with an estimated 12% CAGR, reaching US$35.6 billion by 2032.
• Cardiac Biomarkers: These are specific substances released during heart conditions, aiding early diagnosis of cardiac issues.
• Cardiovascular Disease: The leading cause of death worldwide, driven by lifestyle changes and habits.
• Unavailable Testing Kits: Lack of kits in underdeveloped regions impedes market expansion.
• Type Dominance: Troponin leads with a 29.6% market share, thanks to specificity and early detection.
• Key Indication: Acute coronary syndrome holds the largest share (50.2%) due to rising cases.
• Testing Location: Laboratory testing dominates with a 64.6% share, while point of care testing is growing.
• R&D Opportunities: Investment in efficient testing kits offers significant market opportunities.
• Trending Factors: Urbanization increases demand for cardiac biomarkers, and troponin tests gain popularity.
• Regional Leader: North America leads with a 39.6% market share due to its developed healthcare sector.

Driving Factors

The Increasing Prevalence of Cardiovascular Diseases in the Last Few Years is Driving the Growth of the Cardiac Biomarkers Market.

The rate of deaths and fatalities due to cardiovascular diseases has risen significantly in the last few years. Cardiovascular diseases are the leading cause of death in many parts of the world. Some of the main reasons for cardiovascular diseases are smoking, obesity, lifestyle changes, and diabetes.

With changing lifestyles, individuals are found to be more prone to cardiovascular diseases. Therefore, the use of cardiac biomarkers has risen significantly across the world. It helps the individual to detect cardiovascular abnormality by identifying the indications and providing the result based on it. Therefore, the rising Cardiovascular diseases are driving the growth of the global cardiac biomarkers market.

Restraining Factor

The unavailability of Testing kits for Cardiac Biomarkers is Expected to Hamper the Growth of the Global Cardiac Biomarkers Market.

Although the prevalence of cardiovascular diseases has risen significantly in the last few years, the unavailability of cardiac biomarker testing kits in the market is obstructing the growth of the global cardiac biomarkers market.

Cardiac biomarkers are not available in many parts of the world except the developed countries. The underdeveloped and developing countries have limited availability of cardiac biomarkers in market. Therefore, this unavailability of cardiac biomarkers is restricting the growth of the global cardiac biomarkers market.

Moreover, the cardiac biomarker testing kits are said to have a longer time of processing to show the result. Therefore, in emergency cases, the cardiac biomarker testing kits are not providing results in efficient time. This is also restricting the global cardiac biomarkers market from growth.

Type Analysis

Troponin Leads the Type Segment of Global Cardiac Biomarkers Market.

Based on type, the global cardiac biomarkers market is classified into myoglobin, troponin, BNP and NT-proBNP, CK-MB, and other types. Among these types, troponin dominates the type segment by accounting for a major revenue share of 29.6%.

It is also anticipated to continue its fastest growth throughout the forecast period. This massive growth of the troponin is attributed to the parameters like specificity, diagnostic efficiency, and early detection of cardiac events as compared to others in competition.

The increasing prevalence of cardiac events like stroke and myocardial infarction is further boosting the growth of troponin in the global cardiac biomarkers market. Also, BNP and NT-proBNP are also anticipated to grow significantly over the forecast period due to their use in the detection of stress and heart damage.

Indication Analysis

The Rising Number of Individuals with Acute Coronary Syndrome is Leading the Segment in Global Cardiac Biomarkers Market.

The global cardiac biomarkers market is classified into myocardial infarction, congestive heart failure, acute coronary syndrome, and other indications on the basis of indications. Out of these indications, acute coronary syndrome leads the indication segment by holding a major revenue share of over 50.2%.

The rapidly rising number of individuals in developing and underdeveloped countries with the acute coronary syndrome is driving the growth of acute coronary syndrome in the indication segment of the global cardiac biomarkers market. Expanding urbanization and sedentary jobs individuals are the major factors in the increase of acute coronary syndrome patients.

Also, myocardial infarction is expected to grow significantly during the forecast period. Rising cases of myocardial infarction will propel the growth of myocardial infarction in the indication segment of the global cardiac biomarkers market

Location of Testing Analysis

Laboratory Testing Leads the Segment with Major Share of Cardiac Biomarkers Market in Account.

Based on the location of testing, the global cardiac biomarkers market is divided into point of care testing and laboratory testing. Among this location of testing, laboratory testing dominates the segment by covering the major revenue share of 64.6%.

This growth of laboratory testing is owing to the advantages like specificity, sensitivity, cost-efficiency, and scalability. These advantages are propelling the growth of laboratory testing in the location of the testing segment of the cardiac biomarkers market.

However, the point of care testing is expected to experience exponential growth during the forecast period. Increasing use of easy-to-use and highly sensitive point of care troponin tests is expected to boost the growth of point of care testing in the global cardiac biomarkers market.

Key Market Segments

Type

• Myoglobin
• Troponin
• BNP and NT-proBNP
• CK-MB
• Other Types

Indication

• Myocardial Infarction
• Acute Coronary Syndrome
• Congestive Heart Failure
• Other Indications

Location of Testing

• Point of Care Testing
• Laboratory Testing

Growth Opportunity

Research and Development Activities for Efficient Cardiac Biomarker Testing Kits are Expected to Create Many Lucrative Opportunities in the Market.

Many key companies across the world are heavily investing in the research and development of testing techniques for cardiac biomarkers that can detect cardiac events more efficiently and accurately than the current cardiac biomarker tests. This is expected to create many lucrative opportunities in the global cardiac biomarkers market over the forecast period.

Latest Trends

Trends of Urbanization and Increasing Use of Troponin Tests are Boosting the Growth of the Global Cardiac Biomarkers Market.

Rapidly growing urbanization and changing lifestyles of individuals are directly affecting the health of the individuals. Busy working schedules and changing food habits are directly impacting the lives of individuals. Due to this, the cases of Cardiac events like heart attack and cardiac arrest are rising rapidly in the last few years. This trend of urbanization has increased the demand for cardiac biomarkers testing kits in the market, and this is positively fueling the growth of the cardiac biomarkers market.

Also, the wide advantages of troponin tests are becoming increasingly popular to detect cardiac events like congestive heart failure and myocardial infarction. Troponin tests have high efficiency in diagnosis and are also more efficient than the others in the competition. Due to this, individuals are choosing the troponin test over others in competition.

Regional Analysis

North America Region Leads the Global Cardiac Biomarkers Market by Holding Major Share in Account.

North America region dominates the global cardiac biomarkers market by holding a major revenue share of 39.6%. This growth of North America region is due to the presence of a developed healthcare sector in the region.

The healthcare sector of North America region is more advanced than many countries across the world. The adoption rate of cardiac biomarkers is also very high in the North America region than in others. With the rising population in the region, the demand for biomarker testing has also increased significantly within the region. Also, North America is home to many key companies in the cardiac biomarkers market. All these key factors are boosting the growth of the cardiac biomarkers market in the North America region.

After North America, the Asia Pacific region is anticipated to grow at a significant rate over the forecast period. Rising disposable incomes and advanced cardiac biomarkers tests are driving the growth of the cardiac biomarkers market in the Asia Pacific region.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Player Analysis

The key players in the global cardiac biomarkers market are focusing on research and development of advanced techniques and tests for the diagnosis of cardiac events. Major players are adopting various strategies like mergers, acquisitions, partnerships, and collaboration to expand their market share across various regions and strengthen their position in the market.

Market Key Players

• Abbott
• Siemens Healthineers
• Hoffmann-La Roche Ltd.
• Danaher Corporation
• Biomérieux SA
• Creative Diagnostics
• Life Diagnostics
• Becton, Dickinson, and Company
• Thermo Fisher Scientific Inc.
• Novartis AG
• Other Key Players

Recent Developments

• In June 2022, SCIEX, a subsidiary company of Danaher Corporation, launched the Zeno SWATH DIA. It is said to be a significant step towards biomarker discovery and translation workflows.
• In April 2021, Hoffmann-La Roche Ltd launched 5 new applications related to their cardiac biomarkers in combination with Elecys technology. These biomarkers are said to be successful in the detection of cardiac events.

Report Scope